arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Aurinia Pharmaceuticals Inc.

AUPH
$15.84 ▼ -0.29 (-1.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
29 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Aurinia Pharmaceuticals Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.1B
Dividend Yield
Revenue Growth 24.4%
Op. Margin 53.3%
ROIC 5.7%
FCF / Share $0.25
Trailing P/E 60.9x
Price / Book 3.7x
FCF Yield 1.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.70M
↑ +24.4%
Net Income Profit after all expenses
$34.35M
↑ +47.2%
Operating Margin Operating profit as % of sales
53.3%
↑ +23.7% 92th
FCF / Share Free cash flow per share
$0.25
↑ +2528.4%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
95
Returns
97
Cash Quality
39

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 29 quarters